On April 11, 2023 Immunocore Holdings Plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious diseases and autoimmune conditions, reported that management will present at the 22nd Annual Needham Virtual Healthcare Conference (Press release, Immunocore, APR 11, 2023, View Source [SID1234629943]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation is scheduled for Monday, April 17, 2023, at 3:45 p.m. Eastern Daylight Time (EDT).

The presentation will be webcast live and will be available in the ‘Investors’ section of Immunocore’s website at www.immunocore.com. Following the event, a replay of the presentation will be made available for a limited time.

On April 11, 2023 Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, reported that it will present data from 14 studies highlighting advances in precision oncology and cancer screening at the 2023 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, April 14-19 in Orlando, Florida (Press release, Guardant Health, APR 11, 2023, View Source [SID1234629941]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We look forward to sharing new data at AACR (Free AACR Whitepaper), in particular research demonstrating the tremendous possibilities of epigenomic analysis in biomarker discovery and cancer care," said Helmy Eltoukhy, Guardant Health chairman and co-CEO. "These presentations show how gaining deeper insights into the tumor microenvironment can help us identify new potential biomarker targets for therapy and predictive markers for treatment resistance, quantify circulating tumor DNA, and contribute to better-informed patient care."

Multiple studies to be presented at the meeting highlight the new GuardantINFINITY sequencing platform and demonstrate the utility of its methylation sequencing and epigenomic analysis capabilities in biomarker discovery, therapy selection and response monitoring. In particular, studies show that:

Methylome sequencing with a liquid-only approach using the GuardantINFINITY platform can quantify circulating tumor DNA level and change with greater sensitivity and precision than genomic sequencing, making longitudinal ctDNA monitoring accessible to a broader range of patients. (Abstract 3123)
Cancer genomics alone provides little information on tumor phenotype or functional state, which are governed by epigenetic mechanisms, notably methylation of regulatory regions. The analytical validation of the GuardantINFINITY genomic and epigenomic liquid biopsy platform showed its potential for ultra-sensitive ctDNA detection for minimal residual disease and recurrence surveillance, tumor fraction quantitation for therapy monitoring, oncogenic virus detection, immunogenotyping, epigenotyping, and tumor phenotype characterization, representing a new standard in biomarker discovery. (Abstract 6601)
Full List of Guardant Health Presentations

Abstract
Poster

Title

Product

Sunday, April 16 | 1:30 – 5:00 pm

1052

29

Background variability in plasma ctDNA levels in patients with advanced lung cancer in the absence of treatment

Guardant360

Monday, April 17 | 9:00 am – 12:30 pm

LB123

6

Poorer outcomes in EGFR L858R-driven NSCLC treated with osimertinib may be addressed with novel combination of BLU-945 and osimertinib

GuardantINFORM

Monday, April 17 | 1:30 – 5:00 pm

3331

6

Highly sensitive blood-based multi-cancer screening device with tiered specificity based on diagnostic workflow

Shield

3123

9

A method for quantifying circulating tumor DNA level and molecular response using methylome sequencing

GuardantINFINITY

3128

14

Using Kmerizer, a germline and somatic genotyper for immune associated complex alleles in GuardantINFINITY, for immunotherapy response prediction using cfDNA

GuardantINFINITY

3125

21

Validation of a bioinformatic model for classifying non-tumor variants in a cell-free DNA liquid biopsy assay

GuardantINFINITY

Tuesday, April 18 | 1:30 – 5:00 pm

5573

30

Use of circulating tumor DNA (ctDNA) for early assessment of treatment response in patients with non-small cell lung cancer (NSCLC): A real-world (RW) analysis incorporating baseline ctDNA level and molecular response

GuardantINFORM

4264

13

The genomic landscape of RET fusions in non-small cell lung cancer and the impact of co-occurring genomic alterations on the efficacy of selective RET inhibitors

Guardant360

CT278

18

ERBB2 amplification detected in ctDNA as a surrogate for tumor tissue FISH analysis of HER2 status in a phase 1 study with zanidatamab for the treatment of locally advanced or metastatic HER2 expressing cancers

Guardant360

Wednesday, April 19 | 9:00 am – 12:30 pm

6087

27

Mutation and co-mutation landscape of ERBB2 alterations in advanced NSCLC

Guardant360

6744

4

Cell-free DNA detection of alterations in the MAPK pathway in metastatic hormone receptor positive breast cancer: a multi-institutional analysis of incidence and clinical outcomes

Guardant360

6094

2

Longitudinal analysis of PARP inhibitor and platinum resistance in BRCA1/2m breast cancer using liquid biopsy

GuardantINFINITY

6601

6

Analytical validation of a robust integrated genomic and epigenomic liquid biopsy for biomarker discovery, therapy selection, and response monitoring

GuardantINFINITY

6603

8

BRCA1 promoter methylation in sporadic breast cancer patients detected by liquid biopsy

GuardantINFINITY

The full abstracts for Guardant Health and a list of all abstracts being presented at the meeting can be found at the AACR (Free AACR Whitepaper) website here.

For more information and updates from the meeting, follow Guardant Health on LinkedIn and Twitter or visit AACR (Free AACR Whitepaper) booth #2465.

On April 11, 2023 Genomic Testing Cooperative, LCA (GTC) reported that it will be presenting data at the 2023 American Association of Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting demonstrating that its targeted transcriptomic profiling correlates with immunohistochemistry (IHC)-based testing (Press release, Genomic Testing Cooperative, APR 11, 2023, View Source [SID1234629940]). Targeted transcriptomic data generated in GTC’s routine genomic profiling of tumors is used to quantify various IHC-based biomarkers including HER2, PD-L1, estrogen Receptor (ER), androgen receptor and others. GTC studies demonstrate that RNA sequencing of clinically relevant genes using next generation sequencing (NGS) provides reliable quantitative data that can be interpreted objectively. This data when used in artificial intelligence (AI) algorithms can predict levels of PD-L1 not only in tumor cells, but also in inflammatory cells. The current data suggests that transcriptomic data can replace the need for some IHC test and potentially may better address clinically relevant questions such as determining low HER2 level and others.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We believe that transcriptomic profiling is essential in today’s molecular profiling of cancers. Targeted transcriptomic allows us to focus on the clinically relevant genes and provides better dynamic range." stated Dr. Maher Albitar, founder, chief medical officer, and chief executive officer of GTC. "The generated data when used in AI algorithms allows us to develop new clinical applications and answer clinical questions that few years ago, we thought not possible to answer in routine clinical testing. GTC is leading in this field" added Dr. Albitar.

This data will be presented in the following three posters:

– Predicting PD-L1 status in solid tumors using transcriptomic data and artificial intelligence algorithms: Session Date and Time: Tuesday Apr 18, 2023 9:00 AM – 12:30 PM (4337 / 12)

– Real-world transcriptomic biomarkers as replacement for immunohistochemistry and FISH studies in breast cancer: Session Date and Time: Sunday Apr 16, 2023 1:30 PM – 5:00 PM(967 / 18)

– The molecular landscape of premenopausal versus postmenopausal breast cancer in patients without inherited predisposition mutations: Session Date and Time: Sunday Apr 16, 2023 1:30 PM – 5:00 PM (929 / 12)

Visit GTC booth #1775 at AACR (Free AACR Whitepaper) for more detail and highlights on this work and on how to become a member of the Co-Op.

On April 11, 2023 G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, reported that G1’s Chief Executive Officer Jack Bailey and other members of the Executive Team will participate in a fireside chat during the 22nd Annual Needham Virtual Healthcare Conference (Press release, G1 Therapeutics, APR 11, 2023, View Source [SID1234629939]). The fireside chat will take place on Tuesday April 18th at 1:30 PM EDT.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This meeting is being held virtually; the webcast of the event will be accessible on the Events & Presentations page of View Source

On April 11, 2023 Cellectis (the "Company") (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, reported that the first patient in Europe has been dosed in France with its in-house manufactured product candidate UCART22 and completed the 28-day Dose Limiting Toxicity period (Press release, Cellectis, APR 11, 2023, View Source [SID1234629937]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Our team has worked tirelessly to expand our BALLI-01 clinical study (evaluating UCART22) to Europe. Dosing our first patient in France with our UCART22 product candidate manufactured in-house is an important advancement for Cellectis" said Mark Frattini, M.D., Ph.D., Chief Medical Officer at Cellectis. "By targeting the CD22 antigen, we aim at offering a novel therapeutic alternative to patients living with relapsed/refractory B-cell ALL, including those patients who have relapsed or did not respond to CD19-directed therapy. "

UCART22 is an allogeneic CAR T-cell product candidate that targets CD22 and is evaluated in the BALLI-01 clinical study, a Phase 1/2a open-label study designed to evaluate the safety and clinical activity of the product candidate in patients with r/r B-cell ALL. UCART22 is currently the most advanced allogeneic CAR T-cell product in development for r/r B-cell ALL.

With its proprietary GMP manufacturing facilities in both Raleigh (North Carolina) and Paris (France), Cellectis has taken full control of UCART production and manufacturing timelines. Cellectis believes that its off-the-shelf treatment approach, coupled with its ability to manufacture UCART product candidates completely in-house, gives the Company a main advantage on the market: it potentially maximizes the chances for eligible patients to be treated without delay.

In December 2022, Cellectis presented positive preliminary clinical data for UCART22 in a Live Webcast, that support the continued administration of UCART22 after fludarabine, cyclophosphamide and alemtuzumab (FCA) lymphodepletion in patients with r/r B-cell ALL. The BALLI-01 study (evaluating UCART22) is actively enrolling patients with r/r B-cell ALL after FCA lymphodepletion. For more information, eligibility criteria and trial locations, please visit www.clinicaltrials.gov (NCT04150497) or contact [email protected]